Wall Street analysts expect Enanta Pharmaceuticals (NASDAQ:ENTA) to announce earnings per share (EPS) of $0.10 for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Enanta Pharmaceuticals’ earnings, with estimates ranging from $0.07 to $0.12. Enanta Pharmaceuticals posted earnings of ($0.28) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 135.7%. The business is scheduled to announce its next quarterly earnings results on Monday, May 14th.
According to Zacks, analysts expect that Enanta Pharmaceuticals will report full year earnings of $0.86 per share for the current year, with EPS estimates ranging from $0.85 to $0.86. For the next fiscal year, analysts expect that the company will post earnings of ($0.85) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for Enanta Pharmaceuticals.
Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Wednesday, February 7th. The biotechnology company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.05 by $0.73. Enanta Pharmaceuticals had a net margin of 26.35% and a return on equity of 13.33%. The business had revenue of $38.11 million for the quarter, compared to the consensus estimate of $27.26 million.
ENTA has been the topic of several recent research reports. Royal Bank of Canada downgraded shares of Enanta Pharmaceuticals from an “outperform” rating to a “sector perform” rating and set a $54.00 target price on the stock. in a research report on Tuesday, January 2nd. Zacks Investment Research downgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, January 30th. JPMorgan Chase downgraded shares of Enanta Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research report on Thursday, February 8th. BidaskClub downgraded shares of Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 10th. Finally, ValuEngine upgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 1st. Four analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $57.80.
In other Enanta Pharmaceuticals news, Treasurer Paul J. Mellett sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, March 19th. The shares were sold at an average price of $86.48, for a total transaction of $778,320.00. Following the completion of the transaction, the treasurer now owns 96,458 shares in the company, valued at approximately $8,341,687.84. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Nathalie Adda sold 4,225 shares of the firm’s stock in a transaction that occurred on Monday, April 16th. The stock was sold at an average price of $85.58, for a total transaction of $361,575.50. Following the transaction, the vice president now owns 10,225 shares of the company’s stock, valued at approximately $875,055.50. The disclosure for this sale can be found here. 10.56% of the stock is currently owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. raised its holdings in Enanta Pharmaceuticals by 4.3% during the 4th quarter. BlackRock Inc. now owns 2,343,593 shares of the biotechnology company’s stock worth $137,521,000 after purchasing an additional 97,054 shares during the last quarter. First Manhattan Co. raised its holdings in Enanta Pharmaceuticals by 14.5% during the 4th quarter. First Manhattan Co. now owns 1,084,200 shares of the biotechnology company’s stock worth $63,620,000 after purchasing an additional 137,100 shares during the last quarter. Farallon Capital Management LLC raised its holdings in Enanta Pharmaceuticals by 124.3% during the 4th quarter. Farallon Capital Management LLC now owns 925,000 shares of the biotechnology company’s stock worth $54,279,000 after purchasing an additional 512,667 shares during the last quarter. Renaissance Technologies LLC raised its holdings in Enanta Pharmaceuticals by 13.3% during the 4th quarter. Renaissance Technologies LLC now owns 771,600 shares of the biotechnology company’s stock worth $45,277,000 after purchasing an additional 90,500 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in Enanta Pharmaceuticals by 1.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 562,394 shares of the biotechnology company’s stock worth $26,320,000 after purchasing an additional 7,617 shares during the last quarter. Hedge funds and other institutional investors own 73.26% of the company’s stock.
NASDAQ:ENTA traded down $1.91 during mid-day trading on Wednesday, hitting $87.43. 231,069 shares of the company’s stock were exchanged, compared to its average volume of 210,368. Enanta Pharmaceuticals has a fifty-two week low of $29.46 and a fifty-two week high of $95.91. The company has a market cap of $1,646.86, a PE ratio of 96.08 and a beta of 1.07.
ILLEGAL ACTIVITY WARNING: “$0.10 EPS Expected for Enanta Pharmaceuticals (ENTA) This Quarter” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/18/0-10-eps-expected-for-enanta-pharmaceuticals-enta-this-quarter.html.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.
Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.